Description
Accelerate protein formulation development and screening for therapeutic drug development
Protein stability analysis and preventing aggregation are is crucial when developing therapies. That’s why it’s time to leave flow cell imaging behind.
Speed up protein formulation development and screening with Aura PTx. With just 5 µL of a sample, discover a faster way to detect, count and characterize excipients and drug products at earlier stages of therapeutic development.
Now you can quickly identify and count aggregates that form due to degraded polysorbate in your formulation. And with two-channel fluorescence, determine if aggregation in your protein therapy is caused by proteins or polysorbates in your sample – at the same time.
Features:- Learn more with innovative technology. Aura PTx System combines backgrounded membrane imaging (BMI) with two channels of fluorescence membrane microscopy (FMM) to give you protein aggregate data without the need to clean between measurements.
-
ID protein aggregates. Accurately detect excipient degradation within your formulations and distinguish between protein and non-protein particles effortlessly.
-
Monitor polysorbate degradation. With fluorescence applications, you can track polysorbate degradation to confidently evaluate the stability of your product.
-
Analyze small volumes. You only need 5 µL of sample, allowing you to start characterizing protein aggregates earlier in development.